If the ultimate goal for ANP is to develop a drug to a stage where a big pharma can T/O the drug with upfront payment and future royalties (in the case of similarly valued Mipomersen of $325 upfront and upto $1.5billion milestones), there is really no point in consolidating the shares unlike other type of companies.
As for CR, there are three possibilities:
1. SI placement 2. partnering with a pharma 3. SPP
As the funding for Phase 2a is only about $5m, a placement would probably be faster than an SPP.
The partnering could only occur if there is an offer that is superior. Of course this option would help the SP in short term just like when TEVA licensing of ATL 1102 had kept the SP at 5-7c.
ANP Price at posting:
23.0¢ Sentiment: Buy Disclosure: Held
